Vonoprazan in the management of gastric/peptic ulcers: a systematic review of safety data.

Autor: Moraes-Filho JPP; Gastroenterology Department, Medical School, University of Sao Paulo, Sao Paulo, SP, Brazil., Domingues G; Gastroenterology Department, Medical School, State University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil., Chinzon D; Gastroenterology Department, Medical School, University of Sao Paulo, Sao Paulo, SP, Brazil., Guedes JLS; Takeda Pharmaceuticals, Brazil., Santos CY; Takeda Pharmaceuticals, Brazil., Zaterka S; Gastroenterology Department, Medical School, University of Sao Paulo, Sao Paulo, SP, Brazil.
Jazyk: angličtina
Zdroj: Przeglad gastroenterologiczny [Prz Gastroenterol] 2022; Vol. 17 (4), pp. 266-273. Date of Electronic Publication: 2022 Jan 23.
DOI: 10.5114/pg.2022.112777
Abstrakt: Introduction: Although potassium-competitive acid blockers (P-CABs) prompted safety concerns when first developed, they ultimately proved to have a favourable safety profile.
Aim: To assess the safety of vonoprazan in the management of gastroesophageal reflux disease (GERD), peptic ulcers, or gastroduodenal mucosal lesions induced by chronic use of aspirin or non-steroidal anti-inflammatory drugs (NSAIDs).
Material and Methods: From March to June 2021, a literature search was conducted using Medline via PubMed, Cochrane library, Lilacs, SciELO, and Centre for Reviews and Dissemination (CRD) electronic databases. After applying the eligibility criteria, 10 studies were included in this review. Of these 10 articles, vonoprazan was used as initial therapy in 6 and as maintenance therapy in 4. Adverse event rates were similar for vonoprazan and proton-pump inhibitors (PPIs).
Conclusions: Our findings suggest that vonoprazan is a safe option for the management of erosive oesophagitis, gastric/peptic ulcers, or peptic ulcers induced by chronic use of aspirin or NSAIDs.
Competing Interests: DC has received fees as advisory board member for Takeda. JPPMF and GD has received fees as speaker for Takeda. JLSG and CYS are Takeda Pharmaceuticals Brazil full-time employees. Takeda Pharmaceuticals Brazil funded this work.
(Copyright © 2022 Termedia.)
Databáze: MEDLINE
Externí odkaz: